Pernix Therapeutics Holdings (PTX) : Zacks Investment Research ranks Pernix Therapeutics Holdings (PTX) as 2, which is a Buy recommendation. 1 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 3 research analysts is 2.33, which indicates as a Buy.
For the current week, the company shares have a recommendation consensus of Buy. Pernix Therapeutics Holdings (NASDAQ:PTX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $0.78 and $0.72 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $0.83. The buying momentum continued till the end and the stock did not give up its gains. It closed at $0.76, notching a gain of 1.06% for the day. The total traded volume was 6,140,942 . The stock had closed at $0.75 on the previous day.
In a related news, Siegel Barry J, officer (Senior VP and General Counsel) of Pernix Therapeutics Holdings, Inc. had purchased 5,000 shares on August 19, 2015 in a transaction. The price per share was $4.49 and the total amount of the disclosed transaction was $22,450.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.
Pernix Therapeutics Holdings, Inc. (Pernix) is a pharmaceutical company. The Company is engaged in the acquisition, development and commercialization of prescription drugs, primarily for the United States market. The Company focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. The Companys products include Treximet, an analgesic indicated for acute migraine; Silenor (doxepin), a prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla (desvenlafaxine extended-release tablets), for major depressive disorder. The Company distributes its generic products through wholly owned subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc. (Cypress).